Treatment
- abiraterone
- anastrozole
- bicalutamide
- capecitabine
- CAPOX
- carboplatin
- cetuximab
- cisplatin
- crizotinib
- dacarbazine
- docetaxel
- doxorubicin
- epirubicin
- erlotinib
- everolimus
- exemestane
- fluorouracil
- flutamide
- FOLFOX
- FOLFIRI
- fulvestrant
- gefitinib
- gemcitabine
- goserelin
- imatinib
- irinotecan
- lapatinib
- letrozole
- leuprolide
- liposomal doxorubicin
- megestrol acetate
- nab-paclitaxel
- oxaliplatin
- paclitaxel
- panitumumab
- pemetrexed
- pertuzumab
- sorafenib
- sunitinib
- tamoxifen
- temozolomide
- temsirolimus
- topotecan
- toremifene
- trastuzumab
- vemurafenib
epirubicin
Epirubicin forms a complex with DNA by intercalation of its planar rings between
nucleotide base pairs, leading to inhibition of DNA, RNA and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II and results in cytocidal activity.
Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of
double-stranded DNA and interfering with replication and transcription. Epirubicin is also
involved in oxidation/reduction reactions by generating cytotoxic free radicals.
Epirubicin is indicated* as a component of adjuvant therapy in patients with evidence of
axillary node tumor involvement following resection of primary breast cancer.
*Please refer to full prescribing information/package insert for precise indications.
